ZOLAR is a first-in-human, proof-of-concept and biodistribution trial that uses positron emission tomography (PET) to evaluate olaratumab, a monoclonal antibody, as a therapeutic radiopharmaceutical ...

Severe delays on the Jubilee and Elizabeth lines - The Jubilee and Elizabeth lines are seeing severe delays on its services ...

But it has been revealed that nearly half a million Australians a missing out on a related medicines safety net scheme ... Victoria to ban state school logos on shorts, pants, skirts and socks ...

Here's what every nonprofit leader needs to know about turning marketing from a cost center into their organization's most ...

Looking at the 2025 class, North Dakota State's Grey Zabel is the headliner among those who didn't play at the FBS level. The ...

Xenon is hosting booth #1110 in the Exhibit Hall, which is scheduled to open at 11:30 am PT on Saturday, April 6 and close on Wednesday, April 9 at 4:00 pm PT. About Xenon Pharmaceuticals Inc.

Now it controls their trademark Trump defends tariffs, claiming ‘the patient lived’ amid markets meltdown Creating ... to ...

This morning, the Campania Region presented the project for the new Santobono Hospital at the De Sanctis hall, located at via ...

MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease (AKD); Initial Data Expected in Q1 2026MZE782 Phase 1 Healthy Volunteer ...

- NDA supported by data from three randomized, double-blind, placebo-controlled clinical trials in children with ...

Avisi Technologies, a clinical-stage ophthalmic device company, today announced encouraging six‐month interim results from the VITA trial evaluating its VisiPlate® device, an ultrathin, multichannel ...

In today's Morning Rounds newsletter, proposed cuts to cancer research under the Trump administration, a fake CDC page with ...